7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 
      
    		                                         
      net income
    		35,100,000 34,217,000 27,712,000 30,133,000 36,456,000 32,520,000 23,404,000 31,171,000 19,351,000 15,611,000 14,207,000 17,790,000 18,110,000 10,828,000 8,903,000 8,841,000 13,294,000 14,490,000 14,550,000 15,639,000 35,825,000 16,625,000 8,571,000 12,834,000 17,690,000 13,796,000 9,010,000 7,928,000 -7,652,000 10,733,000 10,515,000 320,000 15,103,000 9,865,000 3,963,000 2,976,000 2,567,000 1,873,000 2,738,000 2,989,000 3,229,000 
      adjustments to reconcile net income to net cash flows from operating activities:
    		                                         
      benefit from credit losses on accounts receivable
    		-153,000 575,000 977,000 420,000 173,000 103,000 254,000  806,000 76,000 540,000   493,000 54,000   118,000 32,000   -920,000 1,885,000                   
      reserve for product returns
    		1,333,000 686,000 425,000 515,000 650,000 873,000 1,149,000 1,420,000 481,000 1,347,000 1,151,000 1,025,000 2,006,000 917,000 798,000 866,000 499,000 555,000 574,000 304,000 491,000 709,000 291,000 -18,000 -61,000 76,000 -120,000 63,000 36,000   323,000 588,000 590,000 554,000 534,000 529,000 535,000 473,000 411,000 385,000 
      benefit from credit losses on notes receivable
    		-1,000    0 -2,000 3,998,000                -349,000                   
      amortization on patents and tooling
    		185,000 179,000 178,000 190,000 240,000 197,000 220,000 248,000 328,000 321,000 316,000 322,000 336,000 348,000 353,000 293,000 344,000 315,000 288,000 278,000 203,000 202,000 199,000 194,000 172,000 167,000 167,000 199,000 189,000 276,000 236,000           
      amortization and depreciation
    		7,793,000 7,534,000 7,024,000 7,102,000 7,612,000 7,080,000 7,337,000 7,943,000 7,948,000 7,860,000 7,673,000 7,747,000 7,587,000 7,775,000 7,761,000 7,386,000 7,467,000 7,477,000 7,385,000 7,497,000 6,878,000 6,723,000 6,422,000 6,301,000 5,467,000 5,138,000 5,228,000 5,567,000 5,891,000 5,238,000 5,025,000 4,953,000 5,071,000 4,846,000 2,864,000 1,627,000 1,659,000 1,613,000 1,591,000 1,438,000 1,504,000 
      amortization of debt issuance costs
    		1,511,000 1,504,000 1,498,000 1,500,000 1,485,000 1,021,000 790,000  787,000 786,000 784,000         27,000 27,000 27,000 27,000 27,000 27,000 27,000 27,000 27,000 27,000 27,000 27,000 27,000 23,000 24,000 23,000 24,000 25,000 28,000 26,000 27,000 27,000 
      amortization of operating leases
    		3,828,000 3,926,000 3,903,000 3,659,000 3,472,000 2,977,000 2,976,000 2,944,000 2,919,000 2,871,000 2,750,000 2,732,000 2,702,000 2,592,000 2,473,000 2,519,000 2,478,000 2,357,000 2,338,000 2,326,000 2,328,000 2,189,000 2,045,000                   
      deferred income taxes
    		34,386,000 -6,882,000 -8,791,000 -1,757,000 -7,747,000 -11,549,000 -13,443,000 -5,118,000 -5,742,000 -9,975,000 -26,895,000 -12,473,000 -19,832,000 -12,084,000 -10,650,000 -4,197,000 1,225,000 -3,965,000 -3,178,000 -1,776,000 1,046,000 -3,853,000 1,327,000 1,097,000 2,129,000 -762,000 135,000 -2,374,000 -7,770,000 -1,542,000 204,000 8,848,000 -3,527,000 -1,710,000 -1,123,000 -2,497,000 -1,342,000 -745,000 -253,000 -1,392,000 -35,000 
      change in fair value of contingent liability
    		542,000 11,000 -301,000 3,000 61,000 13,000 31,000 45,000 -4,000 14,000 13,000         -2,000 -304,000 -1,721,000 -568,000             -4,000 -36,000 -130,000 -60,000 -650,000  
      stock-based compensation
    		8,221,000 8,934,000 9,458,000 9,567,000 9,194,000 11,213,000 11,268,000 10,860,000 11,806,000 11,931,000 12,686,000 14,601,000 13,154,000 12,789,000 12,110,000 11,332,000 9,418,000 10,056,000 7,888,000 8,275,000 7,448,000 7,095,000 6,358,000 5,882,000 5,035,000 5,420,000 4,266,000 3,759,000 3,457,000 3,544,000 2,669,000 2,279,000 1,906,000 1,915,000 1,313,000 1,121,000 1,086,000 942,000 852,000 1,149,000 809,000 
      distributions on investments in unconsolidated entities
    		                                         
      (gain on) / income from investments in unconsolidated entities
    		                                         
      changes in operating assets and liabilities
    		                                         
      accounts receivable
    		10,071,000 -4,709,000 6,283,000 -6,154,000 1,757,000 3,842,000 826,000 -21,584,000 11,631,000 1,260,000 -1,843,000 -6,025,000 -13,351,000 -6,599,000 1,629,000 -15,252,000 1,876,000 -4,880,000 -5,685,000 -2,967,000 -4,582,000 5,515,000 -8,064,000 -6,269,000 -5,077,000 -4,174,000 -6,753,000 5,847,000 -2,995,000 -9,137,000 -3,013,000 -569,000 656,000 -3,578,000 1,580,000 -1,844,000 -1,915,000 -4,610,000 -2,812,000 133,000 1,404,000 
      inventory
    		-1,941,000 315,000 -1,859,000 -12,637,000 4,711,000 6,102,000 10,382,000 18,211,000 3,273,000 -900,000 377,000 -3,265,000 -3,998,000 -21,884,000 -11,161,000 -18,824,000 2,711,000 -12,383,000 -2,947,000 -3,438,000 9,029,000 -13,565,000 -2,673,000 -8,503,000 2,917,000 1,819,000 -2,724,000 -6,084,000 -2,188,000 -1,828,000 1,287,000 -560,000 -3,354,000 -2,974,000 3,553,000 962,000 -2,052,000 -1,869,000 -1,109,000 3,102,000 -1,308,000 
      other current and non-current assets
    		-15,126,000 4,036,000 -8,768,000 2,337,000 -5,635,000 1,563,000 -962,000 -7,761,000 5,991,000 1,121,000 -689,000 -1,509,000 -4,958,000 740,000 -3,225,000 -3,544,000 -237,000 -6,397,000 -1,734,000 2,866,000 -2,279,000 2,838,000 -6,108,000 3,926,000 -2,104,000 -2,342,000 -2,367,000               
      accounts payable and other current liabilities
    		-8,579,000 -26,962,000 -12,749,000                                       
      deferred revenue
    		722,000 -283,000 965,000 -452,000 1,104,000 1,695,000 1,327,000 46,000 1,402,000 1,206,000 1,899,000 -103,000 1,127,000 1,622,000 782,000 -1,240,000 1,058,000 1,363,000 1,127,000 -343,000 1,335,000 -565,000 1,604,000 -414,000 -957,000 -556,000 360,000 -698,000 -97,000 -162,000 -545,000 -24,000 2,000 -282,000 -213,000 506,000 -263,000 156,000 237,000 -14,000 744,000 
      operating lease liabilities
    		-3,491,000 -2,919,000 -3,474,000 -3,296,000 -2,420,000 -3,530,000 -3,221,000 -3,618,000 -3,533,000 -3,434,000 -3,362,000 -3,333,000 -3,290,000 -3,125,000 -2,975,000 -3,064,000 -3,068,000 -2,905,000 -2,772,000 -2,750,000 -2,699,000 -2,469,000 -2,259,000 -7,587,000 -77,000                 
      other liabilities
    		-1,256,000 664,000 -737,000 423,000 511,000 3,783,000 -1,007,000 -293,000 315,000 591,000 -3,511,000 1,469,000 1,005,000 -329,000 -65,000 2,244,000 -626,000 103,000 162,000 -415,000 58,000 -898,000 812,000 215,000 30,000 852,000 -694,000 -317,000 -957,000 -150,000 -334,000 -123,000 -198,000 1,701,000 -1,066,000 1,424,000 224,000 501,000 1,076,000 3,647,000 3,944,000 
      cash flows from operating activities
    		70,628,000 22,716,000 24,057,000 56,260,000 77,337,000   39,872,000 62,826,000   34,446,000 10,197,000   19,963,000 37,886,000 24,076,000 21,232,000 35,410,000 18,622,000   23,265,000 980,000   25,732,000 19,774,000 11,684,000 3,520,000 18,642,000 13,809,000 11,767,000 12,969,000 8,694,000 1,325,000 561,000 6,920,000 5,961,000 13,460,000 
      cash flows used in investing activities:
    		                                         
      business acquisition, net of cash acquired
    		-12,321,000 0 -23,412,000     0 0 0 -9,696,000 0                             -217,000 
      additions to property and equipment
    		-4,754,000 -4,552,000 -6,115,000 -2,268,000 -2,807,000 -1,992,000 -3,066,000 -2,168,000 -1,956,000 -995,000 -2,398,000 -556,000 -1,782,000 -24,131,000 -2,171,000 -2,123,000 -1,558,000 -3,312,000 -4,069,000 -5,464,000 -3,561,000 -3,397,000 -3,719,000 -8,664,000 -4,952,000 -2,746,000 -2,962,000 -1,698,000 -3,186,000 -3,084,000 -3,047,000 -2,812,000 -1,938,000 -3,077,000 -2,637,000 -2,945,000 -1,546,000 -2,026,000 -2,538,000 -3,827,000 -4,508,000 
      issuances of notes receivable
    		-805,000 -2,000,000 -21,500,000 0 0 0 -500,000 -150,000 0 0 -300,000 0 0              -20,061,000     -3,000,000 -1,000,000 -3,000,000 -1,000,000 -3,000,000 0 0 -73,000 -89,000 -98,000 
      receipt of payments on notes receivable
    		37,000 20,000 29,000 13,000 12,000 13,000 13,000 15,000 12,000 15,000 13,000 12,000 17,000 16,000 16,000 17,000 37,000 3,000 2,000                       
      capitalized software development costs
    		-274,000 -350,000 -408,000 -515,000 -496,000 -224,000 -408,000 -428,000 -200,000 247,000 -362,000                               
      proceeds from sale of investments in unconsolidated entities
    		                                         
      purchase of investments in unconsolidated entities
    		-357,000                                         
      purchases of other intangible assets
    		    -1,000                                     
      cash flows used in investing activities
    		-17,015,000 -177,809,000 -55,179,000 -8,128,000 -7,394,000 -5,198,000 -3,961,000 -4,231,000 -2,144,000 -6,648,000 -12,943,000 -5,694,000 -33,495,000 -26,975,000 -2,155,000   -3,309,000 -9,067,000   -2,293,000 -7,013,000 -67,525,000 12,480,000 4,654,000 -23,023,000 -4,060,000 -3,186,000 -3,084,000 -3,047,000 -5,812,000 1,020,000 -6,077,000 -157,926,000 -5,945,000 -3,146,000 -2,165,000 -170,000 -4,309,000 -4,823,000 
      cash flows (used in) / from financing activities:
    		                                         
      proceeds from issuance of convertible senior notes
    		   0 0           0 0 0 500,000,000                       
      payments of debt issuance costs
    		   0 -888,000           0 0 -407,000 -15,291,000                 0      
      purchases of capped calls related to convertible senior notes
    		   0 0                                     
      payments of deferred consideration for acquisitions
    		0   0 -2,700,000   0 -17,000                                 
      purchases of treasury stock, including transaction costs
    		-12,252,000 -5,108,000 -5,059,000 0 0   -14,444,000 -6,128,000                                 
      payments of tax withholdings related to vesting of restricted stock units
    		   0 0                                     
      purchases of redeemable noncontrolling interest
    		       0 0                                 
      issuances of common stock from equity-based plans
    		1,126,000 731,000 1,583,000 2,144,000 1,106,000 378,000 6,356,000 469,000 1,616,000 202,000 1,311,000 629,000 1,728,000 583,000 1,080,000 1,295,000 1,542,000 878,000 1,989,000 5,102,000 2,185,000 3,059,000 1,365,000 566,000         1,602,000 1,078,000 473,000  775,000 56,000 371,000   
      cash flows (used in) / from financing activities
    		-11,876,000 -6,118,000 -3,476,000         -27,849,000 1,361,000 -27,585,000 -22,251,000                -4,000           
      effect of exchange rate changes on cash, cash equivalents and restricted cash
    		23,000 -66,000 -118,000 181,000 -157,000 47,000 -180,000 123,000 67,000 -137,000 13,000                               
      net (decrease) / increase in cash, cash equivalents and restricted cash
    		41,760,000 -161,277,000 -34,716,000         903,000 -21,937,000 -28,341,000 -38,367,000                           
      cash, cash equivalents and restricted cash at beginning of the period
    		0 0 1,229,132,000 0 0 0 701,079,000 0 0 0 622,879,000 0 0 0 710,621,000                           
      cash, cash equivalents and restricted cash at end of the period
    		41,760,000 -161,277,000 1,194,416,000 50,457,000 67,304,000 358,224,000 753,147,000 19,144,000 53,593,000 21,072,000 607,270,000 903,000 -21,937,000 -28,341,000 672,254,000                           
      reconciliation of cash, cash equivalents and restricted cash:
    		                                         
      cash and cash equivalents
    		41,721,000 -161,333,000 1,186,195,000  66,066,000 356,662,000 747,877,000  52,928,000 20,613,000 606,428,000  -22,033,000 -28,373,000 671,753,000                           
      restricted cash included in other current assets and other assets
    		39,000 56,000 8,221,000  1,238,000 1,562,000 5,270,000  665,000 459,000 842,000                               
      total cash, cash equivalents and restricted cash
    		41,760,000 -161,277,000 1,194,416,000  67,304,000 358,224,000 753,147,000  53,593,000 21,072,000 607,270,000  -21,937,000 -28,341,000 672,254,000                           
      income from investments in unconsolidated entities
    		 1,141,000 2,313,000                                       
      purchase of investment in unconsolidated entities
    		  -3,773,000 -3,973,000 -4,102,000                                     
      cash flows from operating activities:
    		                                         
      benefit from / (recovery of) credit losses on notes receivable
    		                                         
      inventory write-down
    		       239,000 0                                 
      gain from investment in unconsolidated entity
    		                                         
      accounts payable, accrued expenses and other current liabilities
    		   25,037,000 25,533,000 -34,961,000 4,524,000 4,242,000 5,067,000 4,921,000 -9,617,000 15,135,000 7,757,000 31,496,000 -21,450,000 28,746,000 -2,731,000 13,623,000 -220,000 7,884,000 -11,435,000 17,249,000 83,000 11,979,000 -20,355,000 6,856,000 -9,460,000 2,143,000 27,362,000 8,111,000 -7,001,000 -4,201,000 373,000 7,119,000 483,000 1,156,000 2,034,000 3,607,000 3,661,000 -4,492,000 3,091,000 
      proceeds from sale of investment
    		           0        0                      
      purchases of intangible assets and other assets
    		                                         
      cash flows from / (used in) financing activities:
    		                                         
      payments of acquired debt
    		       -24,000 -2,627,000 80,000 -469,000                               
      cash flows from / (used in) financing activities
    		   2,144,000 -2,482,000      842,000                591,000           -77,000 737,000 105,000  
      net increase / (decrease) in cash, cash equivalents and restricted cash
    		      52,068,000 19,144,000 53,593,000                                 
      income from investment in unconsolidated entity
    		    180,000                                     
      net increase in cash, cash equivalents and restricted cash
    		    67,304,000                                     
      adjustments to reconcile net income to net cash flows from / (used in) operating activities:
    		                                         
      cash flows from / (used in) operating activities
    		      49,853,000                12,900,000                   
      purchase of investment in unconsolidated entity
    		       -1,500,000 0 0 -200,000     0 0 0 -5,000,000                       
      cash flows from financing activities:
    		                                         
      cash flows from financing activities
    		      6,356,000          1,260,000 -257,000 376,548,000  1,185,000 1,240,000 46,216,000  12,000   146,000 1,696,000   -1,141,000 895,000 76,000 67,473,000       
      benefit from / (recovery of) credit losses on accounts receivable
    		           -450,000                              
      amortization of debt issuance costs and debt discount
    		                                         
      (gain on) / impairment of investment or intangible assets
    		                                         
      loss on early extinguishment of debt
    		               0 0 0 185,000                       
      purchases of developed technology and other assets
    		       0 0                                 
      repayments of credit facility
    		               0 0 0 -110,000,000 -1,000,000 -1,000,000   -1,000,000 -1,000,000 -1,000,000 -1,000,000 -1,000,000 -1,000,000 -1,000,000 -1,000,000 -73,000,000 -700,000         
      recovery of credit losses on notes receivable
    		           -1,000 1,000 0 -78,000 1,000 1,000 0 -11,000  14,000                     
      gain on investment
    		            0                             
      cash flows used in financing activities:
    		                                         
      cash flows used in financing activities
    		        -7,156,000                                 
      adjustments to reconcile net income to net cash flows used in operating activities
    		                                         
      cash flows used in operating activities
    		          -3,521,000                               
      purchases of treasury stock
    		           -26,978,000 -367,000 -28,168,000 -23,331,000      0 0 -5,149,000                   
      net decrease in cash, cash equivalents and restricted cash
    		          -15,609,000                               
      benefit from excess and obsolete inventory
    		               74,000    273,000                      
      amortization of debt discount and debt issuance costs
    		           784,000 782,000 780,000 780,000 4,233,000 4,191,000 4,149,000 3,250,000                       
      acquired in-process research and development
    		                   0 0 0 3,297,000 0                  
      gain on sale of investment
    		                   0                      
      purchases of in-process research and development
    		                   0 0 0 -3,297,000 0                  
      purchases of patents, patent licenses and developed technology
    		                                         
      proceeds from credit facility
    		                   0 0 0 50,000,000         72,000,000 0 0 67,000,000       
      payments of deferred consideration for business acquisitions
    		               0 -282,000 -728,000 -150,000 -719,000 0                     
      changes in operating assets and liabilities:
    		                                         
      proceeds from investment
    		                                         
      restricted cash included in other assets
    		             32,000 501,000                           
      adjustments to reconcile net income to net cash flows (used in) / from operating activities:
    		                                         
      cash flows (used in) / from operating activities
    		              -13,961,000            -1,187,000               
      adjustments to reconcile net income to net cash from operating activities:
    		                                         
      (recovery of) / benefit from credit losses on accounts receivable
    		                                         
      gain on notes receivable
    		                       0                  
      business acquisitions, net of cash acquired
    		                               0 0 0 -154,289,000       
      issuances or purchases of notes receivable
    		                   -600,000    -29,000 -6,013,000                 
      net increase / (decrease) in cash and cash equivalents
    		                      52,103,000     21,818,000 18,284,000 9,161,000 469,000       -1,681,000 7,487,000 1,757,000  
      cash and cash equivalents at beginning of the period
    		               0 0 0 253,459,000 0 0 0 119,629,000 0 0 0 146,061,000 0 0 0 96,329,000 0 0 0 140,634,000 0 0 0 128,358,000 0 0 
      cash and cash equivalents at end of the period
    		               10,314,000 37,625,000 20,510,000 642,172,000 6,283,000 41,349,000 34,095,000 171,732,000 -44,694,000 13,472,000 28,409,000 122,442,000 21,818,000 18,284,000 9,161,000 96,798,000 11,689,000 15,724,000 5,766,000 63,150,000 5,584,000 886,000 -1,681,000 135,845,000 1,757,000 105,718,000 
      recovery of credit losses on accounts receivable
    		                                         
      cash flows (used in) / from investing activities:
    		                                         
      purchases of patents and patent licenses
    		                   -150,000 0                     
      cash flows (used in) / from investing activities
    		                                         
      net increase in cash and cash equivalents
    		                37,625,000 20,510,000 388,713,000  41,349,000    13,472,000           5,584,000      
      (recovery of) / benefit from credit losses on notes receivable
    		                                         
      (gain on) / impairment of investment
    		                                         
      disposal of property and equipment
    		                           1,125,000 0             
      purchases of treasury stock and repurchases of common stock
    		                                         
      impairment of investment
    		                       0                  
      cash flows from / (used in) investing activities:
    		                                         
      receipt of payment on notes receivable
    		                    16,000 2,004,000 3,000 1,000 24,295,000       0          
      cash flows from / (used in) investing activities
    		                                         
      adjustments to reconcile net income to net cash from / (used in) operating activities:
    		                                         
      benefit from doubtful accounts
    		                       448,000 262,000 200,000 260,000 41,000 51,000 44,000 13,000 813,000 -380,000 -108,000 128,000 233,000 154,000 106,000 155,000 -144,000 31,000 
      benefit from notes receivable
    		                       47,000 0                 
      undistributed losses from equity investees
    		                                   21,000 15,000 33,000 12,000 396,000 97,000 
      investment in cost and equity method investees
    		                                         
      repurchases of common stock
    		                           0 0   0 -7,000   1,000 -3,000   0 0 
      net (decrease) / increase in cash and cash equivalents
    		                          -23,619,000     11,689,000 15,724,000 5,766,000 -77,484,000       
      amortization of operating lease right-of-use assets
    		                        1,358,000 1,460,000 1,478,000               
      issuances of common stock from equity based plans
    		                         701,000 1,591,000 1,146,000 2,696,000 1,562,000 996,000         44,000 116,000 
      adjustments to reconcile net income to net cash (used in) / from operating activities:
    		                                         
      other assets
    		                           5,187,000 4,420,000 -3,929,000 -5,563,000 5,580,000 -2,697,000 -6,093,000 668,000 2,219,000 -1,546,000 -1,709,000 199,000 -821,000 -733,000 
      payments of long-term consideration for business acquisitions
    		                                    -200,000     
      purchases of licenses to patents
    		                                   0    0 0 
      proceeds from issuance of common stock from initial public offering, net of underwriting discount and commission
    		                                       0  
      dividends paid to common stockholders
    		                                       0 0 
      dividends paid to employees for unvested shares
    		                                       0 0 
      dividends paid to redeemable convertible preferred stockholders
    		                                       0 0 
      payments of offering costs
    		                                       0  
      proceeds from early exercise of stock-based awards
    		                                       5,000 0 
      amortization for patents and tooling
    		                                243,000 327,000 247,000  186,000     
      undistributed losses from equity investee
    		                                0         
      investment in cost method investee
    		                                    0    0 
      repayments of notes receivable
    		                                   0 0 0 2,441,000   
      undistributed (gains) / losses from equity investees
    		                                  -5,000       
      impairment of cost method investment
    		                                         
      other
    		                                        27,000 
      distribution from cost method investee
    		                                         
      disposition of marketable securities
    		                                         
      proceeds from issuance of debt, net of debt issuance costs
    		                                         
      repayments of term loan
    		                                         
      payments for long-term business acquisition liabilities
    		                                         
      tax windfall benefit from stock-based awards
    		                                       56,000 416,000 
      proceeds from early exercise of stock options
    		                                         
      tax windfall benefit from stock options
    		                                    2,266,000 93,000 366,000   
      amortization on patents
    		                                      134,000 133,000 134,000 
      goodwill and intangible asset impairment
    		                                         
      gain on release of contingent liability
    		                                         
      purchases of marketable securities
    		                                         
      unrealized gain on derivative instrument
    		                                         
      sale of cost method investee
    		                                         
      gain in change in fair value of contingent liability
    		                                         
      payments of deferred offering costs
    		                                         
      supplemental disclosure of noncash investing and financing activities:
    		                                         
      cash not yet paid for business acquisitions
    		                                         
      contingent liability from business acquisition
    		                                         
      cash not yet paid for capital expenditures
    		                                         
      deferred offering costs in accounts payable, accrued expenses and other current liabilities
    		                                         
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.